The combination of venetoclax and gilteritinib is a highly active and tolerable oral combination regimen that potentially improves
response frequency and depth over existing standards in a high-risk, mutation-defined group of patients with AML.

Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Valera
Duration: 45 mins